Compile Data Set for Download or QSAR
maximum 50k data
Found 240 Enz. Inhib. hit(s) with all data for entry = 11485
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620313(US20230295182, Example 1.45 | US20230295182, Examp...)
Affinity DataIC50:  10nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620309(US20230295182, Example 1.41 | US20230295182, Examp...)
Affinity DataIC50:  12nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620311(US20230295182, Example 1.43 | US20230295182, Examp...)
Affinity DataIC50:  15nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620359(US20230295182, Example 2.09 | ethyl ((5r,8R)-3-(((...)
Affinity DataIC50:  17nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620361(US20230295182, Example 2.11 | ethyl ((5r,8R)-3-(((...)
Affinity DataIC50:  19nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620360(US20230295182, Example 2.10 | ethyl ((5r,8R)-3-(((...)
Affinity DataIC50:  20nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620283(US20230295182, Example 1.15 | US20230295182, Examp...)
Affinity DataIC50:  35nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620383(3-(((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylph...)
Affinity DataIC50:  36nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620375(2-(((2R,3R,4S,5R,6R)-2-((1-oxa-2-azaspiro[4.5]dec-...)
Affinity DataIC50:  37nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620325((5r,8R)-3-(((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-...)
Affinity DataIC50:  41nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620385(3-(((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylph...)
Affinity DataIC50:  46nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620329((5r,8R)-3-(((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-di...)
Affinity DataIC50:  49nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620350((2R,3R,4S,5R,6R)-6-((4'H-spiro[bicyclo[3.2.1]octan...)
Affinity DataIC50:  50nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620358(N-((5r,8R)-3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydro...)
Affinity DataIC50:  52nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620313(US20230295182, Example 1.45 | US20230295182, Examp...)
Affinity DataIC50:  60nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620349((2R,3R,4S,5R,6R)-6-((4'H-spiro[bicyclo[2.2.1]hepta...)
Affinity DataIC50:  60nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620354(N-((5r,8R)-3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydro...)
Affinity DataIC50:  61nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620141((2R,3R,4S,5R,6R)-2-((1,8-dioxa-2-azaspiro[4.5]dec-...)
Affinity DataIC50:  61nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620357(N-((5r,8R)-3-(((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3...)
Affinity DataIC50:  62nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620304((2R,3R,4S,5R,6R)-6-((1,8-dioxa-2-azaspiro[4.5]dec-...)
Affinity DataIC50:  64nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620279(US20230295182, Example 1.11 | tert-butyl (3-(((2R,...)
Affinity DataIC50:  69nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620356(N-((5r,8R)-3-(((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro...)
Affinity DataIC50:  71nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620387((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl...)
Affinity DataIC50:  74nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620386(2-(((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluoroph...)
Affinity DataIC50:  74nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620290((2R,3R,4S,5R,6R)-6-((1-oxa-2-azaspiro[4.5]dec-2-en...)
Affinity DataIC50:  76nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620282((2R,3R,4S,5R,6R)-6-((1-oxa-2-azaspiro[4.5]dec-2-en...)
Affinity DataIC50:  78nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620215((2R,3R,4S,5R,6R)-2-((8,8-difluoro-1-oxa-2-azaspiro...)
Affinity DataIC50:  79nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620374(2-(((2R,3R,4S,5R,6R)-2-((1,8-dioxa-2-azaspiro[4.5]...)
Affinity DataIC50:  80nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620294((2R,3R,4S,5R,6R)-6-((8,8-difluoro-1-oxa-2-azaspiro...)
Affinity DataIC50:  81nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620388((2R,3R,4S,5R,6R)-6-((1,3-diazaspiro[4.5]dec-1-en-3...)
Affinity DataIC50:  81nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620204((2R,3R,4R,5R,6R)-2-((1,8-dioxa-2-azaspiro[4.5]dec-...)
Affinity DataIC50:  84nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620308((5r,8R)-3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxym...)
Affinity DataIC50:  89nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620376(2-(((2R,3R,4S,5R,6R)-2-((1-oxa-2-azaspiro[4.5]dec-...)
Affinity DataIC50:  90nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620328((5s,8S)-3-(((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-di...)
Affinity DataIC50:  90nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620384(3-(((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylph...)
Affinity DataIC50:  90nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620319(3-(((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylph...)
Affinity DataIC50:  100nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620311(US20230295182, Example 1.43 | US20230295182, Examp...)
Affinity DataIC50:  100nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620345((RS)-3-(((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-met...)
Affinity DataIC50:  100nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620303((2R,3R,4S,5R,6R)-6-((1,8-dioxa-2-azaspiro[4.5]dec-...)
Affinity DataIC50:  110nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620370((2R,3R,4S,5R,6R)-6-(((5r,8R)-8-((2,2-difluoroethyl...)
Affinity DataIC50:  110nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620344((RS)-3-(((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-met...)
Affinity DataIC50:  110nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620317(3-(((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluoroph...)
Affinity DataIC50:  110nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620341((2R,3R,4S,5R,6R)-2-((1-oxa-2-azaspiro[4.5]dec-2-en...)
Affinity DataIC50:  110nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620326((5s,8S)-3-(((2R,3R,4S,5R,6R)-5-hydroxy-6-(hydroxym...)
Affinity DataIC50:  110nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620294((2R,3R,4S,5R,6R)-6-((8,8-difluoro-1-oxa-2-azaspiro...)
Affinity DataIC50:  110nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620289((2R,3R,4S,5R,6R)-6-((1-oxa-2-azaspiro[4.5]dec-2-en...)
Affinity DataIC50:  110nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620324((5s,8S)-3-(((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-...)
Affinity DataIC50:  120nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620342((2R,3R,4S,5R,6R)-4-(4-(2,3-difluoro-4-methylphenyl...)
Affinity DataIC50:  120nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620333((2R,3R,4S,5R,6R)-4-(4-(4-chloro-2,3-difluorophenyl...)
Affinity DataIC50:  120nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGalectin-3(Homo sapiens (Human))
Idorsia Pharmaceuticals

US Patent
LigandPNGBDBM620305((2R,3R,4S,5R,6R)-6-((1,8-dioxa-2-azaspiro[4.5]dec-...)
Affinity DataIC50:  120nMAssay Description:Briefly, compounds are serially diluted in DMSO (working dilutions). ASF-coated 384 well plates are supplemented with 22.8 uL/well of biotinylated hG...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 240 total ) | Next | Last >>
Jump to: